Placebo’s Effect May Depend on Your Genes
Your response to placebos, or dummy medicine, may depend on your genes, according to a new study. People with a gene variant that codes for higher levels of the brain chemical dopamine respond better to placebos than those with the low-dopamine version. The findings, reported online Oct. 23 in the journal PLoS One, could help researchers design medical studies that distinguish the placebo response from the underlying effect of a medicine — the real aim of drug trials.
“This is a possible way to discern who is going to be a placebo responder or nonresponder in a clinical trial,” said study co-author Kathryn Hall of Beth Israel Deaconess Medical Center in Brookline, Mass.
People report feeling better after receiving a placebo, such as a sugar pill or fake treatment, for conditions ranging from chronic pain to Parkinson’s disease. But only some patients respond strongly, and there’s no way to predict who will improve on a placebo. A few studies have provided clues. Differences in versions of the catechol-O-methyltransferase (COMT) gene, which determines levels of dopamine in the brain’s prefrontal cortex, are linked to differences in reward-seeking and pain perception. People with the high-dopamine version, or allele, of the COMT gene feel pain more acutely and seek rewards more strongly than those who have the low-dopamine copy.
That led the researchers to wonder whether the gene modulates placebo response. To find out, Hall and her colleagues analyzed DNA from 104 patients with irritable bowel syndrome who were randomized to one of three groups: One was told they were on the waiting list for treatment, another received a placebo in the form of seemingly real, curt acupuncture, and the third group received fake acupuncture from a caring, warm practitioner who looked patients in the eye, asked about their progress, and even touched them lightly, Hall told LiveScience.
Patients with the high-dopamine version of the gene felt slightly better after seeing the curt, all-business health-care provider that gave placebo acupuncture. But they were six times as likely to say their symptoms improved with a caring practitioner as those with the low-dopamine gene, who didn’t improve much in any group. The findings suggest that medical studies called clinical trials could identify treatment versus placebo effect by grouping patients by gene variant, Hall said. Knowing up front the level of placebo effect for a clinical trial could reduce the cost of the trial significantly by using fewer participants, for instance, she said.
People with the high-dopamine allele of the gene may do well on the placebo with the nurturing treatment because they are generally more attuned to their environments, said University of Michigan psychiatrist Jon-Kar Zubieta, who was not involved in the study.
“It speaks about an interaction between the environment and the gene,” Zubieta said. “It’s very possible that individuals with this allele are more able to process those positive environmental cues.”
Article from: deskarati.com
Tune into Red Ice Radio:
Bruce Lipton - The Biology of Belief
David Crowe - Rethinking AIDS
Anthony Peake & Tom Campbell - Consciousness Creates Reality
Michael Sharp - Consciousness & The Ascension Process
Lloyd Pye - Human Design & Properties of Annunaki Genes
Nick Begich - Hour 1 - Controlling the Human Mind
Dr David Hamilton: Placcebo Effect & Quantum Healing
Dr David Hamilton ’The Science Of Belief’
Biology of Belief - by Bruce Lipton (Documentary)
Marmosets can meditate (and are immune to the placebo effect)
Placebo Effect’s Neural Activity Photographed for First Time
The Placebo Effect - The Triumph of Mind over Body
Latest News from our Front Page
Netanyahu ‘spat in our face,’ White House officials said to say
The White House’s outrage over Prime Minister Benjamin Netanyahu’s plan to speak before Congress in March — a move he failed to coordinate with the administration — began to seep through the diplomatic cracks on Friday, with officials telling Haaretz the Israeli leader had “spat” in President Barack Obama’s face.
“We thought we’ve seen everything,” the newspaper quoted an unnamed senior ...
The Return of the Protected Jewish Minority in Europe
Contrary to the standard narratives of Jewish ‘history,’ a prominent feature of the historical presence of Jews in Europe has been their protected status. The common context for this status was a symbiotic relationship between the Jewish minority and exploitative or tyrannical elites. As agents of the feared elite, as foreigners, as exploiters in their own right, and with interests ...
Truth Revealed: McCain’s ‘Moderate Rebels’ in Syria ARE ISIS
Poor John McCain and Lindsey Graham, Washington’s real first couple. They only want to arm the ‘moderate opposition’ in Syria. Three years on, how come their master plan isn’t working, while ISIS has grown so strong?
Despite what media lauded as, “the largest demonstration in France’s history – bigger than liberation at the end of WWII!” (can you rightly compare the ...
European 'No-Go' Zones: Fact or Fiction?
Comment: This is an interesting article about Muslim no-go Zones in Europe. However, keep in mind that the focus in this piece is not addressing the root of the problem, but a symptom of the problem. Yes, there is an issue with large Islamic colonies in Europe today, but the article mentions nothing about who has changed the immigration laws ...
A Radical Traditionalist Critique of the Anti-Islam Movement
The terrorist attack against the staff at the magazine Charlie Hebdo in Paris shook an entire continent. In a European climate in which protests against the perceived Islamization of our civilizational sphere becomes ever more widespread, showing in increased electoral success for moderate nationalist parties, as well as in expressions of mass public dissent, the recent resurgence of violent Islamic ...
|More News » |